GENinCode PLC (LSX:A3C31Y) Financings
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new Ordinary Shares (Additional Subscription Shares) Announced: £580,000 · GBX 1 a share Use of proceeds: Additional funding and a longer cash runway while providing the FDA with updates for the De Novo application for its CARDIO inCode-Score test | Feb 6, 2026 | US$789,256 |
| New Ordinary Shares (WRAP Retail Offer) Closed: £200,000 raised · GBX 1 a share · Winterflood Securities Limited Dealers: Winterflood Securities Limited | Jan 26, 2026 | US$273,712 |
| Private placement of new ordinary shares (Placing Shares) Announced: £2.6M · GBX 1 a share · Cavendish Capital Markets Limited +2 Dealers: Cavendish Capital Markets Limited (co-lead), Oberon Capital (co-lead), Turner Pope Investments (TPI) Ltd (co-lead) Use of proceeds: US commercialisation and scale-up, EU and UK expansion, fundraising costs and general working capital | Jan 21, 2026 | US$3.49M |
| Private placement of new ordinary shares (Subscription Shares) Announced: £900,000 · GBX 1 a share Buyers: Nestor Oller (entities associated with existing shareholder Nestor Oller, with certain Directors, to subscribe for 87,300,000 Subscription Shares raising £0.9 million in aggregate) Insiders: Certain Directors intend to subscribe alongside entities associated with Nestor Oller | Jan 21, 2026 | US$1.21M |
| Private placement of new ordinary shares Update: Cavendish Capital Markets Limited +1 Dealers: Cavendish Capital Markets Limited (co-lead), Oberon Capital (co-lead) Buyers: Santi-1990 SL (Nestor Oller) (9,459,460 shares) | Mar 3, 2025 |